Real-World Evidence for Teclistamab in Myeloma | Dr. Rakesh Popat Shares #EHA2025 Insights

Discover the latest real-world data on Teclistamab for relapsed/refractory multiple myeloma, presented by Dr. Rakesh Popat at #EHA2025. Learn how this bispecific antibody therapy is performing outside of clinical trials, what it means for patient outcomes, and how it’s shaping the future of myeloma care.

📌 Key topics covered:

Efficacy and safety in real-world settings
Comparison with clinical trial outcomes
Patient selection and management strategies
Don’t miss this important update from the European Hematology Association Congress 2025!

#Myeloma #Teclistamab #RealWorldData #EHA2025 #MultipleMyeloma #CancerResearch #Immunotherapy #BispecificAntibody

Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Видео Real-World Evidence for Teclistamab in Myeloma | Dr. Rakesh Popat Shares #EHA2025 Insights канала HealthTree University for Multiple Myeloma